Joint system quantum descriptions arising from local quantumness

Bipartite correlations generated by non-signalling physical systems that admit a finite-dimensional local quantum description cannot exceed the quantum limits, i.e., they can always be interpreted as distant measurements of a bipartite quantum state. Here we consider the effect of dropping the assumption of finite dimensionality. Remarkably, we find that the same result holds provided that we relax the tensor structure of space-like separated measurements to mere commutativity. We argue why an extension of this result to tensor representations seems unlikely

Олесь Бабій - співець слави січових стрільців

The Salamanca Formation of the San Jorge Basin (Patagonia, Argentina) preserves critical records of Southern Hemisphere Paleocene biotas, but its age remains poorly resolved, with estimates ranging from Late Cretaceous to middle Paleocene. We report a multi-disciplinary geochronologic study of the Salamanca Formation and overlying Río Chico Group in the western part of the basin. New constraints include (1) an 40Ar/39Ar age determination of 67.31 ± 0.55 Ma from a basalt flow underlying the Salamanca Formation, (2) micropaleontological results indicating an early Danian age for the base of the Salamanca Formation, (3) laser ablation HR-MC-ICP-MS (high resolution-multi collector-inductively coupled plasma-mass spectrometry) U-Pb ages and a high-resolution TIMS (thermal ionization mass spectrometry) age of 61.984 ± 0.041(0.074)[0.100] Ma for zircons from volcanic ash beds in the Peñas Coloradas Formation (Río Chico Group), and (4) paleomagnetic results indicating that the Salamanca Formation in this area is entirely of normal polarity, with reversals occurring in the Río Chico Group. Placing these new age constraints in the context of a sequence stratigraphic model for the basin, we correlate the Salamanca Formation in the study area to Chrons C29n and C28n, with the Banco Negro Inferior (BNI), a mature widespread fossiliferous paleosol unit at the top of the Salamanca Formation, corresponding to the top of Chron C28n. The diverse paleobotanical assemblages from this area are here assigned to C28n (64.67–63.49 Ma), ∼2–3 million years older than previously thought, adding to growing evidence for rapid Southern Hemisphere floral recovery after the Cretaceous-Paleogene extinction. Important Peligran and “Carodnia” zone vertebrate fossil assemblages from coastal BNI and Peñas Coloradas exposures are likely older than previously thought and correlate to the early Torrejonian and early Tiffanian North American Land Mammal Ages, respectively

Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera

Multivalent antigen display is a fast-growing area of interest toward broadly protective vaccines. Current nanoparticle-based vaccine candidates demonstrate the ability to confer antibody-mediated immunity against divergent strains of notably mutable viruses. In coronaviruses, this work is predominantly aimed at targeting conserved epitopes of the receptor binding domain. However, targeting conserved non-RBD epitopes could limit the potential for antigenic escape. To explore new potential targets, we engineered protein nanoparticles displaying coronavirus prefusion-stabilized spike (CoV_S-2P) trimers derived from MERS-CoV, SARS-CoV-1, SARS-CoV-2, hCoV-HKU1, and hCoV-OC43 and assessed their immunogenicity in female mice. Monotypic SARS-1 nanoparticles elicit cross-neutralizing antibodies against MERS-CoV and protect against MERS-CoV challenge. MERS and SARS nanoparticles elicit S1-focused antibodies, revealing a conserved site on the S N-terminal domain. Moreover, mosaic nanoparticles co-displaying distinct CoV_S-2P trimers elicit antibody responses to distant cross-group antigens and protect male and female mice against MERS-CoV challenge. Our findings will inform further efforts toward the development of pan-coronavirus vaccines

COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge

Vaccine-associated enhanced respiratory disease (VAERD) was previously observed in some preclinical models of SARS and MERS coronavirus vaccines. We used the SARS-CoV-2 MA10 mouse model of acute lung injury to evaluate the immune response and potential for immunopathology in animals vaccinated with research-grade mRNA-1273. Whole-inactivated virus or heat-denatured spike protein subunit vaccines with alum designed to elicit low-potency antibodies and Th2-skewed CD4+ T cells resulted in reduced viral titers and weight loss postchallenge, but more severe pathological changes in the lung compared to saline-immunized animals. In contrast, a protective dose of mRNA-1273 induced favorable humoral and cellular immune responses that protected from viral replication in the upper and lower respiratory tract upon challenge. A subprotective dose of mRNA-1273 reduced viral replication and limited histopathological manifestations compared to animals given saline. Overall, our findings demonstrate an immunological signature associated with antiviral protection without disease enhancement following vaccination with mRNA-1273

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusion state, improving their expression and increasing immunogenicity1. This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the prefusion conformation. Here we show that mRNA-1273 induces potent neutralizing antibody responses to both wild-type (D614) and D614G mutant2 SARS-CoV-2 as well as CD8+ T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a phase III trial to evaluate its efficacy

Erratum: "A Gravitational-wave Measurement of the Hubble Constant Following the Second Observing Run of Advanced LIGO and Virgo" (2021, ApJ, 909, 218)

[no abstract available

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Background: Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important to evaluate in nonhuman primates. Methods: Nonhuman primates received 10 or 100 μg of mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein of SARS-CoV-2, or no vaccine. Antibody and T-cell responses were assessed before upper- and lower-airway challenge with SARS-CoV-2. Active viral replication and viral genomes in bronchoalveolar-lavage (BAL) fluid and nasal swab specimens were assessed by polymerase chain reaction, and histopathological analysis and viral quantification were performed on lung-tissue specimens. Results: The mRNA-1273 vaccine candidate induced antibody levels exceeding those in human convalescent-phase serum, with live-virus reciprocal 50% inhibitory dilution (ID50) geometric mean titers of 501 in the 10-μg dose group and 3481 in the 100-μg dose group. Vaccination induced type 1 helper T-cell (Th1)-biased CD4 T-cell responses and low or undetectable Th2 or CD8 T-cell responses. Viral replication was not detectable in BAL fluid by day 2 after challenge in seven of eight animals in both vaccinated groups. No viral replication was detectable in the nose of any of the eight animals in the 100-μg dose group by day 2 after challenge, and limited inflammation or detectable viral genome or antigen was noted in lungs of animals in either vaccine group. Conclusions: Vaccination of nonhuman primates with mRNA-1273 induced robust SARS-CoV-2 neutralizing activity, rapid protection in the upper and lower airways, and no pathologic changes in the lung. (Funded by the National Institutes of Health and others.)